Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
agent, ALT, Amgen, aminotransaminase, amplified, asthenia, committee, comprising, daily, DC, DCR, DL, East, enzyme, ERK, evidenced, exon, exploration, explore, exploring, extracellular, fatigue, fourth, involuntary, low, Middle, morale, nausea, nil, October, paired, pause, pausing, pERK, pharmacodynamic, phosphate, phosphorylated, QD, refunded, reprioritization, RNA, Sanofi, serum, spanning, subgroup, tissue, TRAE, underway, vomiting
Removed:
capable, concept, detail, proof, resistant, underrepresented
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view